Linda Vahdat

Linda Vahdat

UNVERIFIED PROFILE

Are you Linda Vahdat?   Register this Author

Register author
Linda Vahdat

Linda Vahdat

Publications by authors named "Linda Vahdat"

Are you Linda Vahdat?   Register this Author

100Publications

2671Reads

45Profile Views

Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysis.

Breast Cancer Res Treat 2019 Aug 14;176(3):535-543. Epub 2019 May 14.

Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 8th Floor, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05208-wDOI Listing
August 2019

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

N Engl J Med 2019 02;380(8):741-751

From the Massachusetts General Hospital Cancer Center (A.B., S.J.I.) and Dana-Farber Cancer Institute (S.M.T.), Harvard Medical School, Boston; Vanderbilt-Ingram Cancer Center, Nashville (I.A.M., V.G.A.); Weill Cornell Medical College (L.T.V.) and New York-Presbyterian-Columbia University Irving Medical Center (K.K.), New York; University of Colorado Cancer Center, Aurora (J.R.D.); Texas Oncology, Baylor University Medical Center, US Oncology, Dallas (J.O.); Orlando Health University of Florida Health Cancer Center, Orlando (R.L.M., N.C.S.); Yale University School of Medicine, New Haven, CT (A.D.S.); University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (H.S.R.); Immunomedics, Morris Plains, NJ (D.M.G., R.I., S.W., R.M.S., W.A.W.); and AIS Consulting, Ann Arbor, MI (A.M.S.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1814213
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1814213DOI Listing
February 2019

Copper Depletion as a Therapeutic Strategy in Cancer.

Met Ions Life Sci 2019 Jan;19

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/9783110527872-018DOI Listing
January 2019

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.

J Clin Oncol 2018 11 21;36(31):3134-3143. Epub 2018 Sep 21.

Cristina Cruz and Judith Balmaña, Vall d'Hebron Hospital; Cristina Cruz, Alba Llop-Guevara, Joaquín Arribas, Ana Vivancos, Violeta Serra, and Judith Balmaña, Vall d'Hebron Institute of Oncology; José A. Pérez Fidalgo, Ana Lluch, Joaquín Arribas, and Violeta Serra, Centro de Investigación Biomédica en Red; Joaquín Arribas, Institució Catalana de Recerca i Estudis Avançats, Barcelona; José A. Pérez Fidalgo and Ana Lluch, Hospital Clínico de Valencia, Valencia; Cristian Fernández, Carmen Kahatt, Carlos M. Galmarini, Arturo Soto-Matos, Vicente Alfaro, and Aitor Pérez de la Haza, PharmaMar, Madrid; Silvia Antolin, Complejo Universitario Hospitalario La Coruña, La Coruña; Rafael Lopez, Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Judy E. Garber, Dana Farber Cancer Institute; Nadine M. Tung, Beth Israel Deaconess Medical Center; José Baselga and Steven J. Isakoff, Massachusetts General Hospital Cancer Center, Boston, MA; Banu K. Arun, MD Anderson Cancer Center, Houston, TX; Melinda L. Telli, Stanford University School of Medicine, Stanford, CA; Susan M. Domchek, University of Pennsylvania, Philadelphia, PA; and Linda Vahdat, Weill Cornell Medicine, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.6558DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209089PMC
November 2018

Functional Peptide Nanofibers with Unique Tumor Targeting and Enzyme-Induced Local Retention Properties.

Adv Funct Mater 2018 Oct 14;28(44). Epub 2018 Sep 14.

Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine, 413 East 69 Street, New York, NY 10021, USA,

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/adfm.201803969
Publisher Site
http://dx.doi.org/10.1002/adfm.201803969DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261308PMC
October 2018

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.

Lancet Oncol 2018 06 26;19(6):812-824. Epub 2018 Apr 26.

Breast Cancer Unit and Gynaecological Tumours, Ramon y Cajal University Hospital, Madrid, Spain; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Baselga Oncology Institute, Quiron Group, Madrid and Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30147-5DOI Listing
June 2018

Sacituzumab govitecan: an antibody-drug conjugate.

Expert Opin Biol Ther 2017 08 22;17(8):1027-1031. Epub 2017 May 22.

a Department of Medicine , Weill Cornell Medicine , New York , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2017.1331214DOI Listing
August 2017

An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis.

Cell Rep 2017 08;20(7):1623-1640

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Cellular and Developmental Biology, Weill Cornell Medical College, New York, NY, USA; Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2017.07.052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985663PMC
August 2017

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

J Clin Oncol 2017 Jul 14;35(19):2141-2148. Epub 2017 Mar 14.

Aditya Bardia, Steven J. Isakoff, and Dejan Juric, Massachusetts General Hospital Cancer Center; Aditya Bardia, Steven J. Isakoff, Dejan Juric, and Sara M. Tolaney, Harvard Medical School; Sara M. Tolaney, Dana-Farber Cancer Institute, Boston, MA; Ingrid A. Mayer, Vandana Abramson, and Jordan Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN; Jennifer R. Diamond and Wells A. Messersmith, University of Colorado Cancer Center, Aurora, CO; Rebecca L. Moroose and Nikita C. Shah, University of Florida Health Cancer Center, Orlando, FL; Alexander N. Starodub, Indiana University Health Center for Cancer Care, Goshen, IN; Joyce O'Shaughnessy, Texas Oncology-Baylor Charles A. Sammons Cancer Center; Joyce O'Shaughnessy, US Oncology, Dallas, TX; Kevin Kalinsky, Columbia University Herbert Irving Comprehensive Cancer Center; Allyson J. Ocean and Linda T. Vahdat, Weill Cornell Medicine, New York, NY; Michael Guarino, Helen F. Graham Cancer Center, Newark, DE; William A. Wegener, Pius Maliakal, Robert M. Sharkey, Serengulam V. Govindan, and David M. Goldenberg, Immunomedics, Morris Plains, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.8297DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559902PMC
July 2017

Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer.

Support Care Cancer 2017 03 9;25(3):701-708. Epub 2016 Nov 9.

Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-016-3441-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598352PMC
March 2017

Copper suppression as cancer therapy: the rationale for copper chelating agents in mutated melanoma.

Melanoma Manag 2016 Sep 2;3(3):207-216. Epub 2016 Sep 2.

Melanoma Program, Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, 25176 Morris Bldg, DUMC 3198, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt-2015-0005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094647PMC
September 2016

Smart Nanotransformers with Unique Enzyme-Inducible Structural Changes and Drug Release Properties.

Biomacromolecules 2016 06 24;17(6):2040-9. Epub 2016 May 24.

Molecular Imaging Innovations Institute, Department of Radiology, Weill Cornell Medicine , 413 East 69th Street, New York, New York 10021, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.biomac.6b00227DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594411PMC
June 2016

Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.

Nature 2015 Nov 11;527(7579):472-6. Epub 2015 Nov 11.

Department of Cardiothoracic Surgery, Weill Cornell Medical College of Cornell University, 1300 York Avenue, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature15748DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662610PMC
November 2015

Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients Receiving Adjuvant Docetaxel and Cyclophosphamide Chemotherapy.

Clin Breast Cancer 2015 Oct 26;15(5):332-4. Epub 2015 Jan 26.

Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2015.01.003DOI Listing
October 2015

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

J Clin Oncol 2015 May 6;33(14):1609-19. Epub 2015 Apr 6.

Denise A. Yardley, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Robert Weaver, Florida Cancer Specialists, Tampa, FL; Michelle E. Melisko, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco; Scott Cruickshank, Scott Cruickshank & Associates, Santa Barbara; Agustin A. Garcia, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA; Mansoor N. Saleh, Georgia Cancer Specialists, Sandy Springs, GA; Francis P. Arena, New York University Langons Arena Oncology, Lake Success; Tessa Cigler and Linda T. Vahdat, Weill Cornell Medical College, New York, NY; Andres Forero, University of Alabama, Birmingham, AL; Alison Stopeck, University of Arizona Cancer Center, Tucson, AZ; Dennis Citrin, Cancer Treatment Centers of America/Midwestern Regional Medical Center, Zion; Ira Oliff, Orchard Healthcare Research, Skokie, IL; Rebecca Bechhold, Oncology Hematology Care, Cincinnati, OH; Randa Loutfi, Henry Ford Health System, Detroit, MI; and Elizabeth Crowley, Jennifer Green, Thomas Hawthorne, Michael J. Yellin, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.2959DOI Listing
May 2015

Remodeling of the methylation landscape in breast cancer metastasis.

PLoS One 2014 1;9(8):e103896. Epub 2014 Aug 1.

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America; Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0103896PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118917PMC
April 2015

Disease-free survival according to the use of postmastectomy radiation therapy after neoadjuvant chemotherapy.

Clin Breast Cancer 2015 Apr 11;15(2):128-34. Epub 2014 Nov 11.

Department of Radiation Oncology, New York Presbyterian-Hospital/Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2014.09.012DOI Listing
April 2015

Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Breast Cancer Res Treat 2015 Jan;149(1):313

Leeds Institute of Cancer and Pathology and St James's Institute of Oncology, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-3245-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643566PMC
January 2015

Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.

Clin Breast Cancer 2014 Dec 2;14(6):405-12. Epub 2014 Jun 2.

Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2014.04.004DOI Listing
December 2014

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.

Breast Cancer Res Treat 2014 Dec 8;148(3):553-61. Epub 2014 Nov 8.

Leeds Institute of Cancer and Pathology and St James's Institute of Oncology, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-3144-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243003PMC
December 2014

Novel data in metastatic breast cancer.

Authors:
Linda T Vahdat

Clin Adv Hematol Oncol 2013 ;11(10 Suppl 16):13-5

Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
November 2014

New developments in metastatic breast cancer: general discussion.

Clin Adv Hematol Oncol 2013 ;11(10 Suppl 16):16-7

View Article

Download full-text PDF

Source
November 2014

New developments in metastatic breast cancer: integrating recent data into clinical practice.

Clin Adv Hematol Oncol 2013 ;11(10 Suppl 16):1-18; quiz 19

University of California San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
November 2014

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

J Clin Oncol 2014 Nov 29;32(32):3619-25. Epub 2014 Sep 29.

Johanna Bendell and Suzanne Jones, Sarah Cannon Research Institute, Nashville, TN; Mansoor Saleh, Georgia Cancer Specialists, Atlanta, GA; April A.N. Rose and Peter M. Siegel, Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers; Surendra Sirpal, Hematology Oncology Associates, Lake Worth, FL; Jennifer Green, Elizabeth Crowley, Ronit Simantov, Tibor Keler, and Thomas Davis, Celldex Therapeutics; and Linda Vahdat, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.5683DOI Listing
November 2014

Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.

Oncologist 2014 Apr 28;19(4):318-27. Epub 2014 Mar 28.

University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Weill Cornell Medical College, New York, New York, USA; Jules Bordet Institute, Brussels, Belgium; University of Leeds and St James's Institute of Oncology, Leeds, UK; Formerly of Eisai Ltd, Hatfield, UK; Eisai Inc., Woodcliff Lake, New Jersey, USA; NJS Associates Company, Somerset, New Jersey USA; Baylor-Charles A. Sammons Cancer Center, Texas Oncology, and US Oncology, Dallas, Texas, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2013-0282DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983814PMC
April 2014

BreastPRS is a gene expression assay that stratifies intermediate-risk Oncotype DX patients into high- or low-risk for disease recurrence.

Breast Cancer Res Treat 2013 Jun 18;139(3):705-15. Epub 2013 Jun 18.

Department of Pathology and Laboratory Medicine, New York-Presbyterian Hospital, Weill Cornell Medical College, 525 East 68th Street, Starr 1031E, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-013-2604-0DOI Listing
June 2013

Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration.

Cancer Cell 2013 Jan;23(1):63-76

Department of Cardiothoracic Surgery, Weill Cornell Medical College of Cornell University, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2012.11.019DOI Listing
January 2013

Breast cancer subtypes in Asian-Americans differ according to Asian ethnic group.

J Immigr Minor Health 2012 Oct;14(5):754-8

Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10903-012-9577-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051206PMC
October 2012

Microenvironmental regulation of epithelial-mesenchymal transitions in cancer.

Cancer Res 2012 Oct 20;72(19):4883-9. Epub 2012 Sep 20.

Department of Cardiothoracic Surgery, Neuberger Berman Lung Cancer Research Center, Weill Cornell Medical College of Cornell University, New York, New York10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-12-1223DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649848PMC
October 2012

Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition.

Cancer Res 2012 Mar 26;72(6):1384-94. Epub 2012 Jan 26.

Department of Cardiothoracic Surgery and Neuberger Berman Lung Cancer Center, Weill Cornell Medical College of Cornell University, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-11-2905DOI Listing
March 2012

The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.

Expert Opin Biol Ther 2012 Feb 9;12(2):259-63. Epub 2012 Jan 9.

Weill Cornell Medical College, Division of Hematology and Oncology, Department of Medicine, 425 East 61st Street, 8th floor, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2012.642357DOI Listing
February 2012

Eribulin mesylate.

Clin Cancer Res 2011 Nov 22;17(21):6615-22. Epub 2011 Aug 22.

Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medical College, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-1807DOI Listing
November 2011

Novel treatment options in the management of metastatic breast cancer.

Clin Adv Hematol Oncol 2011 May;9(5 Suppl 10):1-16

Clinical Cancer Research Groups, Leeds Institute of Molecular Medicine and St James's Institute of Oncology, Leeds, England.

View Article

Download full-text PDF

Source
May 2011

Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy.

Breast Cancer Res Treat 2010 Oct 10;123(3):837-42. Epub 2010 Aug 10.

Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe, Box 1354, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-010-1102-xDOI Listing
October 2010

Eribulin mesylate for the treatment of breast cancer.

Expert Opin Pharmacother 2010 Jun;11(9):1587-93

Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, 425 East 61st Street - 8th Floor, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2010.486790DOI Listing
June 2010

The effect of a contemplative self-healing program on quality of life in women with breast and gynecologic cancers.

Altern Ther Health Med 2010 May-Jun;16(3):30-7

Center for Complementary and Integrative Medicine, Weill Cornell Medical College, New York, New York, USA.

View Article

Download full-text PDF

Source
June 2010

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.

Clin Breast Cancer 2010 Apr;10(2):160-3

Leeds Institute of Molecular Medicine, St. James University Hospital, Leeds, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2010.n.023DOI Listing
April 2010

Novel combinations for the treatment of metastatic breast cancer.

Authors:
Linda T Vahdat

Cancers (Basel) 2010 Jan 14;2(1):1-19. Epub 2010 Jan 14.

Weill Cornell Medical College, 425 East 61st Street, 8th Floor, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers2010001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827587PMC
January 2010

Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression.

Biochim Biophys Acta 2009 Aug 19;1796(1):33-40. Epub 2009 May 19.

Department of Cardiothoracic Surgery, Lehman Brothers Lung Cancer Research Center, Cornell University Medical Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S0304419X0900028
Publisher Site
http://dx.doi.org/10.1016/j.bbcan.2009.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649840PMC
August 2009

Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.

Clin Breast Cancer 2008 Dec;8 Suppl 4:S166-70

Weill Cornell Medical School, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CBC.2008.s.013DOI Listing
December 2008

Choosing a taxane for adjuvant treatment of breast cancer: more than a flip of the coin?

Authors:
Linda Vahdat

Nat Clin Pract Oncol 2008 Oct 2;5(10):570-1. Epub 2008 Sep 2.

Breast Cancer Research Program, Weill Medical College of Cornell University, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncponc1215DOI Listing
October 2008

Clinical studies with epothilones for the treatment of metastatic breast cancer.

Authors:
Linda T Vahdat

Semin Oncol 2008 Apr;35(2 Suppl 2):S22-30; quiz S40

Division of Hematology/Oncology, Weill Medical College of Cornell University, New York, NY 20021.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2008.02.003DOI Listing
April 2008

Epothilones: clinical update and future directions.

Oncology (Williston Park) 2008 Apr;22(4):408-16; discussion 416, 421, 424 passim

Weill Cornell Breast Center, Cornell University/ New York-Presbyterian Hospital, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
April 2008

Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.

Authors:
Linda Vahdat

Oncologist 2008 Mar;13(3):214-21

Breast Cancer Research Program, Weill Medical College of Cornell University, 425 E. 61st, 8th Floor, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2007-0167DOI Listing
March 2008

Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer.

Breast Cancer Res Treat 2008 Jan 15;107(1):133-8. Epub 2007 Feb 15.

Department of Medicine, Division of Hematology/Oncology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10549-007-9519
Web Search
http://link.springer.com/10.1007/s10549-007-9519-6
Publisher Site
http://dx.doi.org/10.1007/s10549-007-9519-6DOI Listing
January 2008

Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.

Breast Cancer Res Treat 2007 Dec 15;106(3):315-8. Epub 2007 Feb 15.

Division of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York, NY, 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-007-9518-7DOI Listing
December 2007

Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.

Clin Cancer Res 2007 Sep;13(17):5133-43

Department of Microbiology, College of Physicians and Surgeons, Columbia University, New York, NY 10027-6902, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-07-0507DOI Listing
September 2007

The presentation of contralateral axillary lymph node metastases from breast carcinoma: a clinical management dilemma.

Breast J 2007 Mar-Apr;13(2):158-64

Department of Surgery at the New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1524-4741.2007.00390.xDOI Listing
April 2007

Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.

J Clin Oncol 2006 Jul 12;24(19):3013-8. Epub 2006 Jun 12.

New York Phase II Consortium, Albert Einstein Cancer Center, Montefiore Medical Center-Weiler Division, Department of Oncology, 2 S, Room 47-48, 1825 Eastchester Rd, Bronx, NY 10461, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.04.9114DOI Listing
July 2006

Dermatological toxicity of ixabepilone.

Anticancer Res 2006 May-Jun;26(3B):2279-80

Division of Oncology, Department of Internal Medicine, New York-Presbyterian Weill Cornell Medical Center, New York, NY, USA.

View Article

Download full-text PDF

Source
July 2006

Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse.

Cancer Invest 2005 ;23(3):208-14

Department of Pathology-Transfusion Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1081/cnv-200055954DOI Listing
June 2005

Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies.

Support Care Cancer 2004 Sep;12(9):619-25

Division of Hematology/Medical Oncology, Weill Medical College of Cornell University, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-004-0657-7DOI Listing
September 2004

Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: etiology and emerging therapies.

Support Cancer Ther 2004 Jul;1(4):213-8

Division of Hematology/Medical Oncology, Weill Medical College of Cornell University, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/SCT.2004.n.013DOI Listing
July 2004